Presented by Dr Sam Taylor BVetMed(Hons) CertSAM DipECVIMCA FRCVS, the series is aimed at the whole practice team, from new grads to experienced surgeons and nurses.
The sessions are:
Virbac says the series "provides a practical, flexible learning format that fits around busy clinical schedules, offering clear guidance on diagnosis, treatment and longterm management."
https://www.virbac-hub.co.uk
Bluetongue Serotype 8 was detected in the SouthWest of England towards the end of last year's vector season and has since been confirmed in the SouthEast, including East Sussex.
The vaccine can be used during pregnancy and lactation and carries a zero-day withdrawal period.
Sarah Kearney, Product Manager at Virbac, said: "We understand the pressure livestock farmers are under regarding the threat of Bluetongue."
"By making Syvazul BTV 8 vaccine available now, we are enabling vets and farmers to implement vaccination protocols early, so providing the best possible defence for their animals."
The webinar, "The Thyronorm Precision Masterclass: navigating comorbidities, compliance and complex cases", will be presented by Sam Taylor, an RCVS Recognised Specialist in Feline Medicine based at Lumbry Park.
The session will look at balancing thyroid control alongside CKD, cardiac disease and other common concurrent conditions.
It will also cover approaches for improving long-term treatment success in the home environment.
Sam will also cover challenging presentations, atypical progressions and decision-making frameworks for case management.
Registration is free, and the webinar will also be available on demand after the live event.
https://membership.elearning.vet/sam-taylor-thyronorm-free-webinar-registration
Canixin L is an inactivated bacterial vaccine used to stimulate active immunity in dogs against two serogroups of Leptospira interrogans: Canicola and Icterohaemorrhagiae.
The new vaccine is licensed to reduce infection, clinical signs, kidney colonisation, renal lesions and shedding in the urine.
Virbac says Canixin L will play a crucial role in minimising the risk of the disease in both the individual and other animals that may come into contact.
It is licensed for use in dogs from 8 weeks of age, with a second injection administered 3 to 4 weeks later.
Virbac says that for the Canicola serogroup, Canixin L offers the highest level of protection, including prevention of mortality.
Rain Beckles – Product Manager, said: “Virbac is pleased to be able to offer Canixin L, allowing those using Canixin DHPPi/L to vaccinate with L2 only in the intermediate years.
“It also provides an excellent opportunity for practices with clients specifically requesting an L2 vaccine.”
https://uk.virbac.com
Marketed since 2016, Thyronorm is an award-winning liquid formulation that simplifies administration compared to tablets and enables precise dosing for both veterinary surgeons and pet owners.
During the product handover veterinary practices can continue to buy Thyronorm from their usual wholesaler, and all practice support activities and retrospective commercial rebates remain unchanged.
Virbac says it is working closely with Norbrook to make sure all practice support activities are smoothly handed over from Norbrook Account Managers to Virbac Territory Managers.
Vikaly is indicated for the nutritional and medical management of chronic kidney disease in adult and senior cats with proteinuria, from IRIS stage 2.
The new diet delivers the same therapeutic dosage as benazepril tablets (0.5–1 mg/kg bodyweight/day).
Nutrition-wise, Vikaly is low phosphorus (0.5% as fed), has reduced protein (30% as fed), contains omega-3 fatty acids (1.2%, including 0.6% EPA & DHA) and offers high metabolisable energy (416 kcal/100g).
Virbac highlights data showing that CKD remains the leading cause of mortality in cats over five years old and affects up to 40% of feline patients over the age of ten1,2.
The company says administering daily treatment is recognised as a major issue for CKD cat owners with 45% of owners not administering treatment daily as they should and 51% of owners citing administration difficulties as the reason why3.
This new product eliminates the need to administer medication separately, which could completely transform treatment compliance, removing the risk of missed doses and reducing stress for both cats and their owners.
Virbac says that due to the pharmacokinetic profile of benazepril, which is incorporated into the kibble, at an equivalent dose Vikaly displays greater ACE inhibition than benazepril tablets4.
The rate of food consumption also does not affect plasma Benazeprilat levels, ensuring consistent treatment efficacy regardless of the cat’s feeding behaviour5.
Virbac says that in practice, this means that even if the cat being treated consumes less than 50% of their daily ration, efficacy is maintained with ACE activity similar to that of benazepril tablets.
Benazepril has a wide therapeutic margin, tolerated to 20x the minimum effective dose (10mg/kg) for 52 weeks, with the first signs of toxicity being reduced erythrocytes counts & ovary/oviduct weights6.
Virbac says that with Vikaly, these levels cannot be reached because the active ingredient is contained in food, which would require a cat to consume more than 10 times their daily ration.
Vikaly is presented in a 1.5kg bag, which equates to a 30 day supply for a 4.5kg cat with normal bodyweight.
It can be fed alongside wet food, providing that the cat consumes at least 50% of their daily ration before being given the wet food.
The daily ration can also be administered in several smaller meals throughout the day, to accommodate the individual preferences of the cat and to promote consistent food intake.
Vikaly is a prescription diet.
References
The company says the main breakthrough in this new authorisation is that the dose for cattle has been reduced from 4 ml to 2 ml, improving convenience and aligning with the latest regulatory data.
In cattle, the vaccine is indicated for active immunisation to reduce viraemia caused by BTV-3.
The onset of immunity is 3 weeks after completing the primary vaccination course.
The vaccine can be given to cattle from 2 months of age in naïve animals, or from 3 months if born to immune dams.
For the primary vaccination, two doses of 2ml are given, 3 weeks apart, intramuscularly.
In sheep, the vaccine is indicated for active immunisation to reduce viraemia, mortality, clinical signs and lesions caused by BTV-3.
The onset of immunity is 4 weeks after completing the primary vaccination course.
The vaccine can be given to sheep from 3 months of age, subcutaneously.
For the primary vaccination, one dose of 2 ml is given.
https://syva.es/en/
The range includes a spray, collars and diffusers.
Unlike many other pheromone diffusers which need to be plugged into a wall socket, Virbac's uses a patent-pending slow release technology which doesn't need power.
Virbac says the new range has been scientifically proven with published studies which demonstrate not only their effectiveness in managing stress-related behaviours in dogs and cats, but also an equivalent and superior efficacy to the current market leading pheromone products 1,2,3
Andrew Connolly, Virbac's Marketing Director for the UK and Ireland said: "Veterinary professionals have a crucial role to play in supporting their clients with the behavioural management of their pets, both when visiting the practice and at home, and the benefits of pheromones in helping to manage dog and cat behaviour are already very well recognised."
"With Zenidog and Zenifel we hope to make pheromone therapy easier, more cost-effective and better for the environment."
Zenidog and Zenifel are available to order from NVS, Covetrus and VSSCo now.
The modules are 20 minutes long each.
The first: "The Key Components of Successful Anaesthesia", covers the basics of companion animal anaesthesia and analgesia.
The second module: "The Benefits of Zoletil", looks at Zoletil as an anaesthetic and explains the advantages it offers.
Licensed for cats and dogs, Zoletil comprises a coactive balance between Tiletamine & Zolazepam.
Virbac says it is ideal for short and medium duration anaesthesia with multiple administration routes including IV or IM administration, making it a versatile choice of anaesthetic.
https://vet-uk.virbac.com/home/products/dogs/anaesthetics--analgesics/zoletil-100.html
Virbac says this is the only wet product to provide separate species-specific dog and cat convalescence diets tailored to the unique nutritional needs of both species.
In an internal study conduct by Virbac, 86% of dogs with digestive issues improved within a week of using the diet1
The new diets are high in protein and low in carbohydrate and they can be used alone or in combination with the company's dry diets (suggested 50/50 split).
Andrew Connolly, Marketing Director – UK & Ireland at Virbac said: “We’re thrilled with the overwhelmingly positive feedback we've received on our new Veterinary HPM Digestive Support wet diets.
“Practices and pet owners alike are commenting on the extraordinary palatability of the diets and their effectiveness, particularly with convalescing and inappetent pets”.
Despite being one of the most common endocrine diseases in dogs, affecting approximately 1-2 dogs per 1,0001, Cushing’s syndrome can often be difficult to diagnose due to non-specific clinical signs and the lack of a single, highly accurate test.
The webinar is being presented by Professor Carmel Mooney FRCVS, an RCVS Recognised Specialist in Small Animal Medicine (Endocrinology), who will equip attendees with the knowledge and tools to confidently diagnose and treat Cushing’s syndrome and learn the essentials of monitoring trilostane therapy.
Carmel is currently Clinical Director of the University College Dublin Veterinary Hospital, Director of the ECVIM-CA residency programme and Director of the DVMS Professional Doctorate Programme within the School of Veterinary Medicine.
She has published widely in the field of small animal endocrinology with over 80 original articles, reviews and case reports published in peer-reviewed journals, four books as joint editor and 30 book chapters.
https://membership.elearning.vet/cushings-webinarcarmel-mooney
Reference
Trilotab is licensed for the treatment of pituitary-dependent hypercortisolism (PDH) caused by an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma, which accounts for 85% of spontaneous cases of Cushing’s, and for the treatment of adreno-dependent hyperadrenocorticism (ADH) caused by a cortisol-secreting adrenocortical tumour (ACT), which accounts for the remaining 15% of spontaneous cases1.
The new tablet is divisible into halves and quarters to facilitate dose adjustment and make administration easier.
Divided tablets remain stable outside of the blister packaging until the next dose is due, thereby avoiding wastage.
Trilotab tablets are chewable and chicken-flavoured to help improve treatment compliance.
They contain hydrolysed chicken flavouring so they can be prescribed for pets allergic to chicken.
Trilotab is administered once daily with food with a starting dose of 2mg trilostane/kg bodyweight.
The new tabs are available in three presentations: 10mg, 30mg, and 60mg presentations, which Virbac says should help practices reduce their dispensary stockholding.
Andrew Connolly, Marketing Director – UK & Ireland at Virbac, said: ‘The complex nature of Cushing’s syndrome in dogs can make it a challenging condition to manage for both the clinician and the pet owner.
"With the requirement for lifelong treatment, it is our hope that Trilotab’s easy administration and simplified dosing protocols will genuinely help to improve the lives of dogs affected by the disease, whilst making the clinician and pet owner’s lives just a little bit easier too!"
The announcement came hot on the heels of announcements from Ceva and Boehringer that they too had vaccines in the pipeline.
Syvazul BTV3 is licensed to reduce viraemia, prevent mortality and reduce clinical signs and lesions in sheep and for the active immunisation against bluetongue virus serotype 3 in cattle.
Like all vaccines currently available for this serotype, the vaccine will not prevent infection and vaccinated animals will still be subject to bluetongue movement controls and trade restrictions currently in place.
Administered as a single 2ml dose subcutaneously in sheep and as two 4ml intramuscular doses 3 weeks apart in cattle, Syvazul BTV3 contains inactivated Bluetongue virus, serotype 3 (BTV-3), strain BTV-3/NET2023.
The vaccine is licenced for use during pregnancy and lactation in both sheep and cattle.
The onset of immunity is 28 days after the primary vaccine in sheep. A single booster revaccination dose of 2ml for sheep and 4ml for cattle is recommended after 12 months.
Presented in two pack sizes, 80ml and 200ml, Syvazul BTV3 vaccine has a shelf life of 2 years from manufacture and a broach life of 10 hours.
Licensing for use will be geographic, based upon high risk counties or by specific licence from the APHA.
Nominated by a colleague, Will graduated and joined the practice in 2021, having previously worked as a dairy herdsperson.
In his nomination, clients described Will as having an excellent understanding of the practicalities of running a herd, and said he provides realistic and achievable advice.
The judging panel was impressed by Will’s dedication to improving health, welfare, and productivity on dairy farms with his clear advice and workable action plans.
In addition, Will set up an embryo transfer service, bringing a new service to his practice, along with a robot discussion group, all of which have made a significant and positive impact to his dairy farming clients.
Will said: “It was a real privilege to be awarded the Young Dairy Vet of the Year award amongst so many talented and dedicated farm vets in our line of work.
"Above all it is a testimony to the farmers I work with day to day and the proactive attitude they take to improving their systems which has given me so many opportunities to develop my career”.
This year’s runner up was Hana Ward of Torch Vets in Barnstaple, Devon.
Photo: Will with last year's winner, Tom Warboys.
'Otitis Externa: Understanding Ear Disease’ will be presented by RCVS Recognised Specialist in Veterinary Dermatology, Stephen Shaw BVetMed CertSAD DVD PhD PgCAP FHEA MRCVS (pictured).
Virbac says the webinar will explain how Cortotic can help you reduce antimicrobial use when treating otitis externa in dogs, whilst offering the same efficacy as a fixed-combination product.
https://bit.ly/CortoticWebinar
Bordetella bronchiseptica is a clinically significant pathogen for canine infectious respiratory disease (CIRD), otherwise known as kennel cough, with 78.7% of dogs with acute respiratory signs testing positive for the bacteria1.
In the same study, 45.6% of clinically healthy dogs also tested positive for Bordetella bronchiseptica, illustrating that clinically healthy dogs can carry respiratory pathogens and could act as sources of infection for susceptible dogs1.
Administered via subcutaneous injection, Canigen Bb is an inactivated subunit vaccine which offers vets a new option when intra-nasal vaccination with a live aerosolised vaccine is not possible or preferred, for example when the dog is in contact with known immunocompromised individuals.
Licensed for use in dogs from 6 weeks of age, Canigen Bb extends protection against Bordetella bronchiseptica in dogs vaccinated with Canigen KC in the last 12 months for a further year with a single dose.
Canigen Bb is presented as a ready-to-use formula in a 10ml multi-dose bottle and can be stored at room temperature (2°C - 25°C) for up to 4 weeks once broached.
It can be administered concurrently (at the same time but separate injections) with Canigen DHP, Canigen DHPPi, Canigen Pi & Canigen Lepto 4.
Andrew Connolly, Marketing Director at Virbac, said: ‘It is our hope that Canigen Bb will increase the overall uptake of Bordetella bronchiseptica vaccination to provide increased protection against this widely prevalent and clinically significant disease’.
Virbac highlights research which shows that 90% of all dogs over one year are affected by dental issues, including plaque, tartar, gingivitis and halitosis1, but small breed dogs are 5 times more likely to have dental issues than large breeds2.
The new formulation of Veterinary HPM Small & Toy range contains Ascophyllum Nodosum, which Virbac says has been scientifically proven activity on four aspects of oral and dental health: calculus index, volatile sulphur compound concentration, plaque index and gingival bleeding index3.
Virbac points to research which shows that after being absorbed in the small intestine and then secreted into the oral cavity via saliva, Ascophyllum Nodosum inhibits some pathways involved in plaque or calculus development4.
Nutrition-wise, Virbac says the new diet offers 33% less carbohydrate and 34% more protein, on average, compared to other brands sold in veterinary practices5.
90% of the protein included in the diets is also from animal protein.
The updated range also features 2 new kibble sizes (10.5mm & 7.5mm), for smaller mouths.
Cortotic contains hydrocortisone aceponate (HCA), a diester glucocorticosteroid to reduce inflammation.
In a clinical field study, published in Veterinary Dermatology, Cortotic was shown to be as effective in treating acute otitis as a fixed-combination product containing a corticosteroid, an antibiotic and an antifungal, with an equivalent improvement of clinical and cytological scores1.
A secondary reduction of bacterial and yeast overgrowth was demonstrated and a concomitant treatment with an antimicrobial was unnecessary.
The product was shown to provide rapid relief from clinical signs, pruritus and pain1.
Virbac says the lipophilic nature of the HCA diester provides enhanced penetration into the skin, a reservoir effect and low plasma availability for high local activity with reduced systemic secondary effects2.
Chris Newark, Product Manager at Virbac said: "With Cortotic we’re excited to offer clinicians the ability to reduce antimicrobial usage when treating otitis externa in dogs, whilst offering the same efficacy as a fixed-combination product.
"The product’s easy administration also makes it an attractive choice for pet owners with 94% of owners stating that they would choose to use Cortotic again3".
Cortotic is presented in an ear spray device with atraumatic cannula, which delivers a fine mist spray for even application.
Dosing is 2 pumps per application, whatever the dog’s size, once a day for 7-14 days.
The content covers the main points in the WSAVA’s report and offers up-to-date information and advice.
For example, Virbac highlights how the report raises concerns about increasing moves to early neutering, or for neutering to be used as a method of behavioural control, as not all aggressive behaviours are testosterone related.
For that reason, a “castration trial’ with long-acting GnRH agonist is recommended by the report before irreversible orchiectomy is performed.
In addition, there is also evidence that gonadectomy may contribute to the development of some tumours, which is currently under intense investigation, as is the effect of age at castration
Dr Neil Mottram, Technical Manager at Virbac, said: "There is so much new information coming through that vets need to assimilate.
"So the educational reproductive resource is designed to make that journey easier to navigate and provide vets with easy access to up to the minute information on key issues in the report’.
To access the materials visit: https://vet-uk.virbac.com/home/resource-library.html, or contact your territory manager.
Produced in association with Farmers Guardian, information in the guide includes the role of Multimin in increasing farm margins by reducing mastitis, improving fertility, assisting growth and increasing immunity.
The Multimin Focus Guide also includes case studies that demonstrate how livestock performance can be elevated with trace minerals, which is relevant to both the dairy and beef industries.
Sabrina Jordan, Product Manager at Virbac said: "Multimin is a unique injection that is designed to ‘top up’ trace mineral supplies at critical times of the production cycle.
"Strategic use of Multimin supports the transition cow and is increasingly used to increase fertility in maiden heifers, particularly at second lactation.
"Multimin is particularly useful for youngstock where it helps to boost immunity and growth; and supports during times of stress such as transportation and grouping.
"Most significantly, in areas where vets have identified deficiencies in grazing pasture, Multimin can ensure that animals are 'topped up' with the appropriate trace minerals to optimise performance.
"The aim of this online resource is to support vets in demonstrating the importance of trace minerals to improving herd efficiency and health."
www.farmersguardian.com/bringing-herd-health-virbac-multimin-focus
The 1st Reproduction Control Guidelines of the World Small Animal Veterinary Association (WSAVA) have just been accepted for publication and are expected to recommend a move away from a blanket neutering policy.
Dr Neil Mottram BSc (Hons) BVSc MRCVS Technical Manager at Virbac said: "This webinar will help clinicians understand and navigate the latest evidence-based medicine in regards to neutering.
"The panel of world-leading experts on reproduction will present their guidance on medical and surgical neutering and offer delegates the opportunity to interact with a live Q&A section at the end of the event.
https://app.livestorm.co/virbac-france/1st-reproduction-control-guidelines?type=detailed
Containing 3% m/v Chlorhexidine, Pyoderm is designed to support the natural microbial balance of the skin whilst delivering gentle yet effective cleansing.
Along with the rest of Virbac's range of dermatological and everyday care shampoos, Pyoderm is presented in 250ml eco-friendly bottles which are made from 100% recycled plastic and recyclable packaging.
The shampoos themselves are also biodegradable.
https://uk.virbac.com/
A single vial can now be used for 8 days after reconstitution when stored in a fridge at between two and eight degrees celsius.
This, says Virbac, will help maximise the use of each vial, ultimately reducing wastage and providing a cost-effective solution.
The broached bottle must be kept refrigerated between 20C and 80C until the next use.
Virbac says that whilst this may not seem a huge change, it significantly increases the cost-effectiveness and convenience to farmers.
The SPC changes mean that
Bovigen Scour is available in 5 and 30 dose bottles.
Virbac says Michelle is widely recognised as one of the world’s leading experts in companion animal reproductive biology.
She graduated from Washington State University College of Veterinary Medicine, before completing a residency at Cornell University and becoming board-certified in Theriogenology.
She earned a PhD in physiology at Cornell University and is currently a Full Professor at Oregon State University.
Michelle is also a member of the WSAVA Reproduction Control Committee which recently previewed its new Global Guidelines for Reproduction Control during WSAVA Congress in September.
Dr Neil Mottram MRCVS, Technical Manager at Virbac said: "The UK has the highest rate of surgical castration in Europe, but with new WSAVA global reproduction control guidelines expected to be published imminently, increasing evidence on the effect of surgical castration on long-term health and even the UK’s leading animal welfare charities updating their guidance on neutering dogs, there’s no better time to review practice neutering policies.
"In line with an evidence-based approach, we want to pose the question: is surgical castration right for every dog?"
www.bit.ly/caninecastration